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Abstract:
Introduction: Adjudication of the primary outcome in randomised trials is thought to control
misclassification. We investigated the amount of misclassification needed before adjudication
changed the primary trial results.
Methods: We included data from five randomised stroke trials. Differential misclassification was
introduced for each primary outcome until the estimated treatment effect was altered. This was
simulated 1000 times. We calculated the between-simulation mean proportion of participants that
needed to be differentially misclassified to alter the treatment effect.
In addition, we simulated hypothetical trials with a binary outcome and varying sample size (1000-
10000), overall event rate (10-50%), and treatment effect (0.67-0.90). We introduced non-differential
misclassification until the treatment effect was non-significant at 5% level.
Results: For the five trials, the range of unweighted kappa values were reduced from 0.89-0.97 to
0.65-0.85 before the treatment effect was altered. This corresponded to 2.1%-6% of participants
misclassified differentially for trials with a binary outcome. For the hypothetical trials, those with a
larger sample size, stronger treatment effect and overall event rate closer to 50% needed a higher
proportion of events non-differentially misclassified before the treatment effect became non-
significant.
Discussion and Conclusion: For trials without adequate blinding, central adjudication is vital to
control for differential misclassification. However, for large blinded trials adjudication is of less
importance and may not be necessary.
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1. Introduction:
In randomised trials, outcomes are commonly assessed by site investigators at each trial site. For
studies with many sites, random error (non-differential misclassification) could be introduced into
outcome assessment through inexperience of site investigators or varied practice across sites.
Furthermore, for open-label trials with inadequate blinding of treatment allocation, there is the
possibility of detection bias in the assessment of outcomes, with site investigators misclassifying
outcomes differently between arms (differential misclassification). Hróbjartsson et al.[1] showed that,
on average, unblinded site investigators exaggerate treatment effects for subjective binary outcomes
by 36%.
To control for differential and non-differential misclassification, many trials use a central adjudication
committee, made up of blinded independent experts who assess the trial outcome in addition to the
site investigators. The central adjudicators’ assessment of the outcome is often used in preference to
that of the site investigators. Central adjudication is commonly included in vascular trials[2], including
those that are investigating stroke[3, 4], although the value of adjudication has been questioned[5-7].
We have previously carried out a systematic review and meta-analysis that included 15 randomised
stroke trials where both central adjudicators and site investigators assessed the primary outcome[8]. In
this systematic review, we found no evidence that central adjudication of a trial’s primary outcome
altered the treatment effect estimate compared with the estimate obtained using site reported data
(pooled ratio of treatment effects (RTE)=1.02, 95% C.I:[0.95, 1.09]). This result concurred with two
other meta-analyses investigating the impact of adjudication of binary outcomes on the treatment
effect estimates[6, 7].
The aim of the present simulation study was to investigate whether there are circumstances when
central adjudication of a trial’s primary outcome would change the primary treatment effect estimate.
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2. Methods:
To investigate when central adjudication changes a trial’s results we can explore how much
differential misclassification by site investigators was necessary to alter the estimated treatment
effect, i.e. the 95% confidence interval of the RTE excludes the null value, one. However, this
investigation ignored the statistical significance of the treatment estimate pre- and post-
misclassification and only identified when the treatment effect estimate differs significantly to the
estimate obtained after central adjudication (RTE≠1). Therefore, for completeness, we considered 
situations where the RTE remained at one after misclassification (here non-differential), and the
significance of the treatment estimate differed pre- and post-misclassification. Thus, in this study we
(1) evaluated how much differential misclassification was needed to alter the estimated treatment
effect; and (2) explored how much non-differential misclassification caused a significant treatment
effect to become non-significant at 5% level.
2.1 Differential misclassification using real trial data:
For studies with adequate blinding, central adjudication should control for non-differential
misclassification by reducing random ‘noise’ around the main estimate of interest. However,
increasing this ‘noise’ in a simulation will not meaningfully shift the estimate of interest, because the
amount of misclassification in a blinded trial should be equal in both treatment arms. Therefore, to
explore the situation where central adjudication does alter the treatment effect estimate, we
introduced differential misclassification. Previous studies have shown that site investigators often
exaggerate treatment effect estimates[1], so we introduced differential misclassification for outcomes
assessed by site investigators to make the treatment effect estimates more beneficial. The starting
point for misclassification was the centrally adjudicated data, as this is the gold standard, and
outcomes were misclassified to increasing extent. This misclassification differs for binary and ordinal
variables, as explained below.
2.1.1 Data collection
Our systematic review of central adjudication in stroke trials included 15 trials totalling 69,650
participants[8]. All included trials had their primary outcome assessed by both site investigators and
central adjudicators, and were asked to provide either summary results or individual patient data
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(IPD). Of the 15 trials in our systematic review, we selected the five trials that provided IPD, as
differential misclassification is introduced at a patient level. The five studies covered a variety of
outcomes, number of participants randomised, and treatment effectiveness[9-14].
The five studies selected corresponded to seven unique populations as one study, NASCET, carried
out separate analyses for patients with mild-, moderate- and severe-grade carotid artery stenosis
(denoted as NASCET:mild, NASCET:moderate and NASCET:severe respectively). Throughout the
remainder of this article these will be referred to as individual trials. Therefore, in this simulation study
there were seven trials included (HAEST, ICSS, REVASCAT, TARDIS, and the three aforementioned
NASCET subpopulations).
2.1.2 Misclassification for binary outcomes
For binary outcomes, differential misclassification was introduced by increasing the proportion of
participants who (a) were in the control arm and had an event, and, (b) were in the treatment arm and
did not have an event. For each trial, varying proportions of participants were randomly misclassified.
Only participants in the control arm without the event and participants in the treatment arm with the
event were misclassified, as the objective was to make the treatment effect estimates more beneficial.
2.1.3 Misclassification for ordinal outcomes
For ordinal outcomes, a similar approach was taken. In both trials where the outcome was analysed in
an ordinal fashion, participants could be allocated one of six categories. To simulate increased
differential misclassification, selected participants in the control arm had their outcome value
increased (worse outcome) and those in the treatment group had their outcome value decreased
(better outcome). As the proportion of participants misclassified in the simulation increased, the
number of participants misclassified by one category, two categories and so on, increased
proportionally. Outcomes were constrained by the minimum (0) and maximum (5) values.
2.1.4 The proportion of misclassification necessary to alter the estimated treatment effect
The number of participants misclassified was increased in 0.1% increments, and, for each increment
the trial’s primary analysis was repeated using the misclassified outcome. The treatment effect was
then compared with the treatment effect based on central adjudicated data (remains constant for each
trial) using the ratio of treatment effects (RTE). An RTE < 1 indicates that the misclassified data
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produces a more beneficial treatment effect. For each 0.1% increment, we ran 1000 simulations, from
which we then calculated the mean RTE and 95% confidence interval. We stopped increasing the
increments when the upper bound of the 95% confidence interval was less than 1 (misclassified
treatment effect is significantly different to the treatment effect based on centrally adjudicated data).
2.1.5 Statistical analysis
We calculated percent agreement and unweighted kappa between central adjudicators and site
investigators for the primary outcome of each trial before misclassification. For trials with ordinal
outcomes, weighted kappa used linear weights was also determined. Each trial was analysed as per
the analysis specified in their main results paper, except for the three NASCET trials, where a
univariate Cox proportional hazards model was fitted for each trial.
After simulation, the within-simulation mean and standard deviation of the treatment effect after
misclassification, number of participants misclassified, crude percent agreement and unweighted (and
weighted if appropriate) kappa were determined for each trial. All analyses, including those described
in the following sections, were undertaken using Stata version 15.1.
2.2 Non-differential misclassification using hypothetical trial data:
For studies with adequate blinding, any misclassification of an outcome is expected to be equal
between treatment and control arms, that is, non-differential. For these studies, the RTE will be close
to one even with introduction of a large amount of non-differential misclassification. However, this
could still impact on trial conclusions by introducing greater random error, resulting in wider 95%
confidence intervals around the estimated treatment effect. Thus, we can estimate the amount of non-
differential misclassification required to cause a loss of precision such that the 95% confidence
interval for a real treatment effect no longer excludes the null.
2.2.1 Data generation
Data was generated using Stata to represent a simple parallel group trial with a binary primary
outcome. We estimated the treatment effect using relative risk and significance level was set at 5%.
We aimed to establish how much non-differential misclassification was required for a previously
significant treatment effect to become non-significant.
2.2.3 Characteristics to vary
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Three different treatment effects were chosen: relative risks of 0.67 (for example, events in a ratio of
3:2 between control and treatment groups respectively), 0.82 (ratio of 11:9) and 0.90 (ratio of 21:19)
to represent strong, moderate and modest treatment effects respectively. In stroke trials overall event
rate is usually low, so we explored situations where the overall event rate was ≤50%.The overall event 
rate was simulated in 10% intervals, from 10% to 50% and additionally at 15%. Finally, the overall trial
sample size was simulated to be either 1000, 2000, 3000, 5000 or 10000. Thus, by varying sample
size, overall event rate and treatment effect there were 90 distinct scenarios. This is summarised in
Table 1. The simulation code is provided in the supplementary material to enable further, more
specific, scenarios to be explored.
2.2.4 Misclassifying events
For each scenario, events were misclassified proportionately in each arm in order to preserve the
relative risk and thus keep the RTE equal to one. The amount of misclassification required for the
95% confidence interval of the relative risk to include the null value of one was expressed as a
percentage of the total number of events in the original dataset.
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3. Findings:
3.1 Differential misclassification using real trial data:
For five of the trials, the primary outcome was binary, whereas for the remaining two trials the primary
outcome was analysed on an ordinal scale (Table 2). The number of participants randomised varied
between 206 (REVASCAT) and 3096 (TARDIS). Using the real data, agreement was high between
central adjudicators and site investigators, with crude agreement ranging from 93.2% to 99.6% and
kappa ranging from 0.89 to 0.97 (Table 3, see Supplementary Tables 1a-1b and 2a-2b).
After simulation of differential misclassification, as planned, the treatment effect was more beneficial
for every trial such that the upper bound of the confidence interval for the RTE was 0.99 (Table 4). For
trials with a binary outcome, between 2.1% and 6% of participants needed to be differentially
misclassified to alter the estimated treatment effect, with the amount of misclassification inversely
associated with study size (Table 4). In the two trials with ordinal primary outcomes, there was
substantial variation in the proportion of participants that needed to be misclassified (1.9% and
27.8%). However, these studies did represent the trials with the largest and smallest number of
participants respectively. Following misclassification, crude agreement remained high for all but one
of the trials, but the kappa values were reduced in the range of 0.65 to 0.85 (Table 5, see
Supplementary Tables 1c-1d and 2c-2d).
3.2 Non-differential misclassification using hypothetical trial data:
For 26 of the scenarios, the initial risk ratio was not significant at 5% before misclassification, so these
cases are not given (displayed as NA in Supplementary Table 3). As expected, more events were
required to be misclassified to change a significant treatment effect to non-significant at the 5% level
when the original treatment effect was strongest (Figure 1, see Supplementary Table 3 and
Supplementary Figures 1-2).
Greater sample size and higher overall event rate both required a larger proportion of events to be
misclassified before significant treatment effects become non-significant (Figure 1). For example, in a
hypothetical blinded trial with 5000 participants, overall event rate of 20% and a modest treatment
effect (relative risk=0.82), 649 (64.9%) of the events would need to be misclassified non-differentially
before a significant treatment would become non-significant.
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4. Discussion:
In this simulation study based on seven distinct stroke trial populations we found that only a small
amount of differential misclassification was needed before central adjudication would have altered the
estimated treatment effect. Larger trials appeared to be most vulnerable to this bias, in part due to
their larger sample size being able to detect a smaller difference in treatment effect. However, for
blinded studies where differential misclassification should not occur, an implausible amount of random
error is required to alter trial conclusions.
Whilst ordinal outcomes could be misclassified by more than one level (i.e. mRS of 1 to 3), it can be
argued that this would be less severe than misclassification of a binary event (0 to 1 or vice versa).
Therefore, the results from binary and ordinal outcomes should not be compared. Overall, we found
that a relatively small amount of differential misclassification was needed to alter the estimated
treatment effect. This suggests that central adjudication is important to control for differential
misclassification in randomised trials. However, three of the five trials included had blinded outcome
assessment, so the plausibility of this amount of differential misclassification happening in practice to
these studies is far less than the unblinded trials. In our review[8] we did not see any indication of
detection bias through differential misclassification, so even the small proportion needed before the
treatment effect changes may be a rare occurrence in trials. One reason for this finding in our review
could be due to 9 (60%) of the included studies having the site investigators blind to treatment
allocation and the majority of the studies had stroke as their primary outcome, which is well defined
and accurately measured[15]. We found no significant interaction between blinding status and RTE, but
this may have been due to the reviews small sample size. A Cochrane review[7] that included 47 trials
which adjudicated subjective binary events did find an interaction between blinding status of the site
investigators and the ratio of odds ratios (RORs), with the suggestion that unblinded site investigators
exaggerate treatment effect estimates (two trials, ROR=0.76, 95% C.I: [0.46, 1.12]). Furthermore,
unblinded site assessors have been shown to exaggerate treatment effect estimates in multiple
studies by Hróbjartsson[1, 16, 17]. Thus, differential misclassification is a real possibility in medical
research, and adjudication can control for this.
However, for blinded studies, we would not expect central adjudication to control for differential
misclassification, and instead only reduce random noise around the effect of interest. As expected,
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the proportion of events needed to be misclassified before a significant treatment effect becomes non-
significant increases with trial size, overall event rate and strength of treatment effect. This can also
vary with method of adjudication, but this is not something we explored in our study. We have shown
for a trial with a binary outcome that a large amount of non-differential misclassification is necessary
before even a modest treatment effect is missed. For the five stroke trials included in the first part of
this study, the largest agreement for a trial with a binary outcome was 98.8%. Far higher
disagreement would have been needed before central adjudication ensures that a modest and
significant treatment effect does not become non-significant through random error. In a previous
simulation study that explored central adjudication of stroke type in a stroke trial with blinded outcome
assessment[18], the agreement between the adjudicators and site investigators was 98% and kappa
had to reduce from 0.92 to 0.46 before a true subgroup effect by stroke type was missed. This
amount of random error is not plausible for many trial settings. Other studies investigating
adjudication in stroke trials found agreement between adjudicators and site investigators of 91% for
all stroke[19], and 90% for stroke[4]. Thus, for large blinded trials, central adjudication could be an
unnecessary expenditure to control for non-differential misclassification. However, it is important to
note that for other non-stroke outcomes commonly assessed in stroke trials, such as coronary events
or fatal vascular events, agreement may not be as high as described above. Adjudication of these
outcomes, especially if they are part of a primary composite outcome such as major adverse
cardiovascular events, could still be warranted in these settings. One alternative approach to site-
assessment followed by adjudication could be to assess outcomes centrally, taking away the need for
site-assessment. However, this approach would only be suitable for those studies with central follow-
up.
One limitation of our study is that we have only focused on adjudication of the primary outcome, and
the high level of agreement we found across the included studies may be lower for different
outcomes. For example, a study exploring adjudication of serious adverse events found agreement
between site investigators and central adjudicators for likely causality of event of 56%[20]. However,
we have chosen a variety of stroke trials that represent acute stroke, primary and secondary
prevention studies as well as including the majority of common primary outcomes in these studies.
Another limitation is that we only explored non-differential misclassification through binary outcomes.
Our justification for this is that the majority of stroke trials included in our review[8] had a binary primary
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outcome. Furthermore, it is possible that trials with ordinal outcomes would need greater
misclassification than those with binary outcomes, due to the ordinal scale the outcome is measured
on.
To conclude, we found that central adjudication is important for stroke trials without sufficient blinding
for outcome assessment through its control of differential misclassification. However, for randomised
stroke trials that do have adequate blinded outcome assessment, central adjudication is less
important and may not be necessary.
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Tables and Figures:
Table 1: Summary of parameters used in the simulation of non-differential misclassification
Description Values
Treatment effect 0.67, 0.82, 0.90
Overall event rate 10%, 15%, 20%, 30%, 40%, 50%
Sample size 1000, 2000, 3000, 5000, 10000
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Table 2: Summary of included trials
mRS refers to modified Rankin Scale
Trial name Population Intervention Comparator Primary outcome Were site
investigators blind
to treatment?
Adjudication
information
HAEST Patients with acute ischaemic
stroke and atrial fibrillation
(n=449).
Dalteparin (n=224) Aspirin (n=225) Recurrent ischaemic
Stroke (binary). Analysed
using logistic regression.
Yes Two clinicians
assessed medical
notes (including
reports from cranial
scans) and original
case report forms with
diagnosis concealed.
ICSS Patients with symptomatic
carotid stenosis (n=1713)
Stenting (n=855) Carotid
endarterectomy
(n=858)
Fatal or disabling stroke
(binary). Analysed using cox
regression.
No Two clinicians
assessed outcome
without knowledge of
site assessment
NASCET Patients with non-disabling
stroke and carotid stenosis of
30-99% in the internal carotid
artery.
There were three populations:
mild (<50%,
n=1368); moderate (50-69%,
n=858); and severe
(70-99%, n=659) stenosis.
Carotid endarterectomy.
In addition,
patients received
medical care,
including antiplatelet
therapy. Mild
(n=678), moderate
(n=430), severe
(n=328).
Medical care,
including
antiplatelet
therapy. Mild
(n=690), moderate
(n=428),
severe (n=331)
Fatal or non-fatal
ipsilateral stroke (binary).
Analysed using Mantel–
Haenszel chi-square test. To
obtain an estimate, we
analysed NASCET trials using
univariate cox regressionl.
No Neurologists and
surgeons assessed
original case report
forms and cranial
scans without
knowledge of site
assessment.
REVASCAT Patients with acute ischaemic
stroke who could be
treated within 8 hours (n=206)
Medical therapy
(including alteplase if
eligible) and
thrombectomy (n=103)
Medical therapy
(including
alteplase if
eligible) (n=103)
Functional outcome at 90
days (mRS, ordinal). Patients
who scored 5 or 6 were
grouped in a single category.
Analysed using ordinal logistic
regression (6 point scale)
Yes Neurologists assessed
audio-tape or video
recording of patient
evaluation of the
primary outcome.
TARDIS Patients with acute ischaemic
stroke or TIA
(n=3096).
Aspirin, clopidogrel and
dipyridamole
(n=1556)
Aspirin and
dipyridamole, or
clopidogrel alone
(n=1540)
Functional outcome and
recurrent stroke and TIA
(ordinal). Analysed using
ordinal logistic regression (6
point scale)
Yes Clinicians assessed
medical notes, original
case report forms and
cranial scans, if
requested.
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Table 3: Agreement between central adjudicators and site investigators on the primary outcome using original trial data
SI refers to Site investigators; CA refers to Central adjudicators
*Unweighted kappa
†Weighted kappa using linear weights
Trial Central adjudicator data Site investigator data Agreement between central
adjudicators and site investigators
Crude
agreement
Kappa
HAEST
Treated Control Treated Control SI CA No event Event
99.6% 0.97*No event 205 208 No event 203 208 No event 411 0
Event 19 17 Event 21 17 event 2 36
ICSS
Treated Control Treated Control SI CA No event Event
98.8% 0.89*No event 808 801 No event 812 802 No event 1600 14
Event 49 52 Event 44 50 event 7 87
NASCET: mild
Treated Control Treated Control SI CA No event Event
98.9% 0.96*No event 589 580 No event 592 584 No event 1165 11
Event 89 110 Event 86 106 event 4 188
NASCET: moderate
Treated Control Treated Control SI CA No event Event
99.2% 0.97*No event 373 348 No event 374 354 No event 721 7
Event 57 80 Event 56 74 event 0 130
NASCET: severe
Treated Control Treated Control SI CA No event Event
99.2% 0.97*No event 300 264 No event 299 268 No event 563 4
Event 28 67 Event 29 63 event 1 91
REVASCAT see Supplementary Table 1a see Supplementary Table 1b 93.2%
0.91*
0.96†
TARDIS see Supplementary Table 2a see Supplementary Table 2b 98.8%
0.91*
0.91†
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Table 4: Number and proportion of participants required to be differentially misclassified to alter estimated treatment effect
Trial (N) Treatment effect before
misclassification (95%
CI)
Mean treatment effect after
misclassification (SD)
Mean number of
participants
misclassified (SD)
Mean percentage of participants
misclassified (SD)
RTE (95% CI)
HAEST (n=449) 1.13 (0.57, 2.24) 0.45 (0.07) 20.4 (4.3) 4.5% (1.0%) 0.40 (0.16, 0.99)
ICSS (n=1710) 0.94 (0.64, 1.39) 0.54 (0.04) 35.9 (5.9) 2.1% (0.3%) 0.59 (0.34, 0.99)
NASCET: mild (n=1368) 0.83 (0.72, 0.95) 0.55 (0.03) 55.0 (7.0) 4.0% (0.5%) 0.68 (0.46, 0.99)
NASCET: moderate (n=858) 0.71 (0.60, 0.84) 0.43 (0.03) 51.4 (6.7) 6.0% (0.8%) 0.63 (0.39, 0.99)
NASCET: severe (n=659) 0.36 (0.28, 0.43) 0.19 (0.02) 39.3 (5.9) 6.0% (0.9%) 0.53 (0.28, 0.99)
REVASCAT (n=206) 0.57 (0.35, 0.95) 0.28 (0.02) 57.2 (5.8) 27.8% (2.8%) 0.48 (0.23, 0.99)
TARDIS (n=3096) 0.90 (0.67, 1.20) 0.59 (0.03) 60.3 (7.3) 1.9% (0.2%) 0.66 (0.44, 0.99)
Data from 1000 simulations (starting seed 2206). Treatment effects lower than one indicates treatment is beneficial. SD refers to standard deviation. RTE refers to ratio of
treatment effects.
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Table 5: Agreement between central adjudicators and site investigators on primary outcome after differential misclassification
Crude agreement and kappa are from 1000 simulations (starting seed 2206). Example site investigator data and example agreement are taken from one of the 1000
simulations. SI refers to Site investigators; CA refers to Central adjudicators
*Unweighted kappa
†Weighted kappa using linear weights
Trial Central adjudicator data Example misclassified site
investigator data
Example agreement between central
adjudicators and misclassified site
investigators
Mean crude
agreement (SD)
Mean kappa
(SD)
HAEST
Treated Control Treated Control SI CA No event Event
95.4% (1.00%) 0.75 (0.05)*No event 205 208 No event 206 189 No event 394 1
Event 19 17 Event 18 36 event 19 35
ICSS
Treated Control Treated Control SI CA No event Event
97.9% (0.34%) 0.84 (0.02)*No event 808 801 No event 811 769 No event 1577 3
Event 49 52 Event 46 84 event 32 98
NASCET: mild
Treated Control Treated Control SI CA No event Event
96.0% (0.51%) 0.85 (0.02)*No event 589 580 No event 594 534 No event 1123 5
Event 89 110 Event 84 156 event 46 194
NASCET: moderate
Treated Control Treated Control SI CA No event Event
94.0% (0.78%) 0.80 (0.02)*No event 373 348 No event 383 320 No event 683 10
Event 57 80 Event 47 128 event 38 127
NASCET: severe
Treated Control Treated Control SI CA No event Event
94.0% (0.88%) 0.79 (0.03)*No event 300 264 No event 303 231 No event 531 3
Event 28 67 Event 25 100 event 33 92
REVASCAT see Supplementary Table 1c see Supplementary Table 1d 72.2% (2.80%)
0.65 (0.03)*
0.84 (0.02)†
TARDIS see Supplementary Table 2c see Supplementary Table 2d 98.1% (0.24%)
0.85 (0.02)*
0.87 (0.02)†
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Figure 1: Amount of non-differential misclassification required such that treatment effect (relative
risk=0.82) is no longer significant at 5% level for various sample sizes and overall event rates
Missing scenarios are due to the initial treatment effect before misclassification being non-significant (p>0.05). n
refers to hypothetical trial sample size
SUPPLEMENTARY MATERIAL:
Supplementary table 1a: Functional outcome by treatment group using central adjudicator and site investigator data in REVASCAT
Central adjudicator data Site investigator data
Outcome Treated
(n=103)
Control
(n=103)
Treated
(n=103)
Control
(n=103)
mRS 0 7 6 6 3
mRS 1 18 7 23 10
mRS 2 20 16 20 16
mRS 3 19 20 15 20
mRS 4 8 17 7 15
mRS 5/6 31 37 32 39
mRS refers to modified Rankin Scale
Supplementary table 1b: Agreement on functional outcome between central adjudicators and site investigators in REVASCAT
Crude agreement = 192/206 = 93%, unweighted kappa = 0.91, weighted kappa using linear weights = 0.96. mRS refers to modified Rankin Scale
Central Adjudicators
Site Investigators mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5/6 Total
mRS 0 9 0 0 0 0 0 9
mRS 1 4 25 3 1 0 0 33
mRS 2 0 0 33 3 0 0 36
mRS 3 0 0 0 35 0 0 35
mRS 4 0 0 0 0 22 0 22
mRS 5/6 0 0 0 0 3 68 71
Total 13 25 36 39 25 68 206
Disagreements (%) 4 (31%) 0 (-) 3 (8%) 4 (10%) 3 (12%) 0 (-) 14 (7%)
Supplementary table 1c: Functional outcome by treatment group using central adjudicator and misclassified site investigator data in REVASCAT
Central adjudicator data Example misclassified
site investigator data
Outcome Treated
(n=103)
Control
(n=103)
Treated
(n=103)
Control
(n=103)
mRS 0 7 6 14 3
mRS 1 18 7 15 7
mRS 2 20 16 21 11
mRS 3 19 20 19 20
mRS 4 8 17 14 19
mRS 5/6 31 37 20 43
Misclassified site investigator data is from one of 1000 simulations (starting seed 2206). mRS refers to modified Rankin Scale
Supplementary table 1d: Agreement on functional outcome between central adjudicators and example misclassified site investigators in REVASCAT (data
from one of 1000 simulations)
Mean crude agreement (SD) = 72.2% (2.80%), mean unweighted kappa (SD) = 0.65 (0.03), mean weighted kappa using linear weights (SD) = 0.84 (0.02). Mean crude
agreement, unweighted and weighted kappa are from 1000 simulations (starting seed 2206). mRS refers to modified Rankin Scale
Central Adjudicators
Site Investigators mRS 0 mRS 1 mRS 2 mRS 3 mRS 4 mRS 5/6 Total
mRS 0 10 7 0 0 0 0 17
mRS 1 3 15 4 1 0 0 22
mRS 2 0 3 24 5 0 0 32
mRS 3 0 0 8 26 4 1 39
mRS 4 0 0 0 8 15 10 33
mRS 5/6 0 0 0 0 6 57 63
Total 13 25 36 39 25 68 206
Disagreements (%) 3 (23%) 10 (40%) 12 (33%) 14 (36%) 10 (40%) 11 (16%) 60 (29%)
Supplementary table 2a: Functional outcome by treatment group using central adjudicator and site investigator data in TARDIS
Central adjudicator data Site investigator data
Outcome Treated
(n=1556)
Control
(n=1540)
Treated
(n=1556)
Control
(n=1540)
No recurrent event 1463 1435 1457 1434
TIA 32 48 34 53
Stroke: mRS 0/1 15 18 16 16
Stroke: mRS 2/3 22 23 23 22
Stroke: mRS 4/5 11 9 13 10
Fatal stroke: mRS 6 13 7 13 5
mRS refers to modified Rankin Scale
Supplementary table 2b: Agreement on incidence and severity of stroke between central adjudicators and site investigators in TARDIS
Crude agreement = 3062/3096 = 98.9%, unweighted kappa = 0.91, weighted kappa using linear weights = 0.91. TIA refers to Transient Ischaemic Attack, mRS refers to
modified Rankin Scale
Central Adjudicators
Site Investigators No recurrent event TIA Stroke: mRS 0/1 Stroke: mRS 2/3 Stroke: mRS 4/5 Fatal stroke: mRS
6
Total
No recurrent event 2881 1 3 4 0 2 2891
TIA 5 77 4 1 0 0 87
Stroke: mRS 0/1 4 2 26 0 0 0 32
Stroke: mRS 2/3 5 0 0 40 0 0 45
Stroke: mRS 4/5 3 0 0 0 20 0 23
Fatal stroke: mRS 6 0 0 0 0 0 18 18
Total 2898 80 33 45 20 20 3096
Disagreements (%) 17 (1%) 3 (4%) 7 (21%) 5 (11%) 0 (-) 2 (10%) 34 (1%)
Supplementary table 2c: Functional outcome by treatment group using central adjudicator and misclassified site investigator data in TARDIS
Central adjudicator data Example misclassified
site investigator data
Outcome Treated
(n=1556)
Control
(n=1540)
Treated
(n=1556)
Control
(n=1540)
No recurrent event 1463 1435 1472 1403
TIA 32 48 31 58
Stroke: mRS 0/1 15 18 16 26
Stroke: mRS 2/3 22 23 17 31
Stroke: mRS 4/5 11 9 10 12
Fatal stroke: mRS 6 13 7 10 10
Misclassified site investigator data is from one of 1000 simulations (starting seed 2206). mRS refers to modified Rankin Scale
Supplementary table 2d: Example agreement on incidence and severity of stroke between central adjudicators and misclassified site investigators in
TARDIS (data from one of 1000 simulations)
Mean crude agreement (SD) = 98.1% (0.24%), mean unweighted kappa (SD) = 0.85 (0.02), mean weighted kappa using linear weights (SD) = 0.87 (0.02). Mean crude
agreement, unweighted and weighted kappa are from 1000 simulations (starting seed 2206). TIA refers to Transient Ischaemic Attack, mRS refers to modified Rankin Scale
Central Adjudicators
Misclassified site
Investigators
No recurrent event TIA Stroke: mRS 0/1 Stroke: mRS 2/3 Stroke: mRS 4/5 Fatal stroke: mRS
6
Total
No recurrent event 2866 4 0 4 0 1 2875
TIA 10 76 2 0 0 1 89
Stroke: mRS 0/1 8 0 31 2 1 0 42
Stroke: mRS 2/3 8 0 0 39 1 0 48
Stroke: mRS 4/5 3 0 0 0 18 1 22
Fatal stroke: mRS 6 3 0 0 0 0 17 20
Total 2898 80 33 45 20 20 3096
Disagreements (%) 32 (1%) 4 (5%) 2 (6%) 6 (13%) 2 (10%) 3 (15%) 49 (2%)
Supplementary Table 3: Number and proportion of non-differentially misclassified events required
such that treatment effect is no longer significant at 5% level
Data are number of events misclassified/total number of events (%)
Significant treatment effect is set at α=0.05 and is from a risk ratio
Proportion of events 60% vs 40% corresponds to a treatment effect of 0.67, a proportion of events 55% to 45%
corresponds to a treatment effect of 0.82, and a proportion of events 52.5% to 47.5% corresponds to a treatment
effect of 0.90. A treatment effect less than one indicates treatment is beneficial.
NA refers to scenarios where the initial treatment effect before misclassification was non-significant (p>0.05)
Overall event rate
Proportion of events:
Treatment vs Control
10% 15% 20% 30% 40% 50%
N=10000
60% vs 40% 910/1000
(91%)
1410/2000
(94%)
1910/2000
(95.5%)
2910/3000
(97%)
3910/4000
(97.75%)
4910/5000
(98.2%)
55% vs 45% 629/1000
(62.9%)
1129/1500
(75.27%)
1629/2000
(81.45%)
2629/3000
(87.63%)
3629/4000
(90.73%)
4629/5000
(92.58%)
52.5% vs 47.5% NA 169/1500
(11.27%)
680/2000
(34%)
1680/3000
(56%)
2680/4000
(67%)
3690/5000
(73.8%)
N=5000
60% vs 40% 405/500
(81%)
660/750
(88%)
905/1000
(90.5%)
1405/1500
(93.63%)
1905/2000
(95.25%)
2405/2500
(96.2%)
55% vs 45% 149/500
(29.8%)
400/750
(53.33%)
649/1000
(64.9%)
1149/1500
(76.6%)
1649/2000
(82.45%)
2149/2500
(85.96%)
52.5% vs 47.5% NA NA NA 329/1500
(21.93%)
829/2000
(41.45%)
1329/2500
(53.16%)
N=3000
60% vs 40% 210/300
(70%)
360/450
(80%)
510/600
(85%)
810/900
(90%)
1110/1200
(92.5%)
1410/1500
(94%)
55% vs 45% NA 109/450
(24.22%)
260/600
(43%)
560/900
(62%)
860/1200
(71.63%)
1160/1500
(77.33%)
52.5% vs 47.5% NA NA NA NA 200/1200
(17%)
499/1200
(41.6%)
N=2000
60% vs 40% 110/200
(55%)
210/300
(70%)
310/400
(77.5%)
510/600
(85%)
710/800
(88.75%)
910/1000
(91%)
55% vs 45% NA NA 80/400
(20%)
280/600
(46.67%)
480/800
(60%)
680/1000
(68%)
52.5% vs 47.5% NA NA NA NA NA 129/1000
(12.9%)
N=1000
60% vs 40% 15/100
(15%)
70/150
(46.67%)
115/200
(57.5%)
215/300
(71.63%)
315/400
(78.75%)
415/500
(83%)
55% vs 45% NA NA NA 29/300
(9.67%)
129/400
(32.25%)
229/500
(45.8%)
52.5% vs 47.5% NA NA NA NA NA NA
Supplemental figure 1: Amount of non-differential misclassification required such that treatment
effect (relative risk=0.67) is no longer significant at 5% level for various sample sizes and overall
event rates
n refers to hypothetical trial sample size
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Supplemental figure 2: Amount of non-differential misclassification required such that treatment
effect (relative risk=0.90) is no longer significant at 5% level for various sample sizes and overall
event rates
Missing scenarios are due to the initial treatment effect before misclassification being non-significant (p>0.05). n
refers to hypothetical trial sample size
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